ClinicalTrials.gg
CompletedNCT00247650Updated Mar 1, 2017

Comparison Study of Letrozole Alone or Letrozole With Zoledronic Acid in Early Breast Cancer, Neoadjuvant Therapy

A Phase 2 interventional study of Zoledronic Acid; Letrozole in Breast Cancer, sponsored by Novartis. Completed at 10 sites in Canada. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-03-01.

Sponsored by Novartis · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
65 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing Zoledronic Acid in Breast Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Zoledronic Acid · Breast Neoplasms.

Planned enrollment
23rd of 56
190 · median 98
Started
2005
with 7 others
Phase 2
11 of 59
none open now
Registered
17th of 59
by date
Lead sponsor
5 of 59
Novartis

Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, this one is the 23rd largest by planned enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2005, is one of 11 in phase 2, and was the 17th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 59 studies testing Zoledronic Acid in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →

About Zoledronic Acid

Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 65 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 59 studies testing Zoledronic Acid in Breast Neoplasms as a file.
02

Study summary

This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • neoadjuvant, postmenopausal women, breast cancer, hormonal therapy, bisphosphonate
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women
  • Newly diagnosed with non breast cancer
  • Candidate for mastectomy or breast-conserving surgery

Exclusion criteria

Exclusion Criteria

  • Patients with invasive tumors
  • Patients receiving anti-cancer treatment
  • Patients who have undergone surgery

Other protocol-defined exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical response at 24 weeks

Secondary outcomes

  1. Clinical response at 16 weeks

  2. Clinical benefit at 16 weeks

  3. Clinical benefit at 24 weeks

  4. Rate of breast conserving surgery in both arms

  5. Rate of complete pathological response

  6. Biomarkers

07

Study locations

10 sites
  • Novartis Investigative Site
    Edmonton, Alberta, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia, Canada
  • Novartis Investigative Site
    Victoria, British Columbia, Canada
  • Novartis Investigative Site
    London, Ontario, Canada
  • Novartis Investigative Site
    Toronto, Ontario, Canada
  • Novartis Investigative Site
    Windsor, Ontario, Canada
  • Novartis Investigative Site
    Granby, Quebec, Canada
  • Novartis Investigative Site
    Montreal, Quebec, Canada
  • Novartis Investigative Site
    Victoriaville, Quebec, Canada
  • Novartis Investigative Site
    Quebec, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a primary completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2005
First posted
Nov 2, 2005
Start
Sep 2005
Primary completionActual
Mar 2007
Last update
Mar 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00247650
Lead sponsor
Novartis
First posted
Nov 2, 2005
Start date
Sep 2005
Primary completion
Mar 2007
Last update
Mar 1, 2017

Study contacts

Novartis
study chair · Novartis
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zoledronic Acid · Letrozole

Start the discussion